Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series*
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia : a case series*. / Brivio, Erica; Chantrain, Christophe F.; Gruber, Tanja A.; Thano, Adriana; Rialland, Fanny; Contet, Audrey; Elitzur, Sarah; Dalla-Pozza, Luciano; Kállay, Krisztián Miklós; Li, Chi kong; Kato, Motohiro; Markova, Inna; Schmiegelow, Kjeld; Bodmer, Nicole; Breese, Erin H.; Hoogendijk, Raoull; Pieters, Rob; Zwaan, Christian Michel.
I: British Journal of Haematology, Bind 193, Nr. 6, 2021, s. 1172-1177.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia
T2 - a case series*
AU - Brivio, Erica
AU - Chantrain, Christophe F.
AU - Gruber, Tanja A.
AU - Thano, Adriana
AU - Rialland, Fanny
AU - Contet, Audrey
AU - Elitzur, Sarah
AU - Dalla-Pozza, Luciano
AU - Kállay, Krisztián Miklós
AU - Li, Chi kong
AU - Kato, Motohiro
AU - Markova, Inna
AU - Schmiegelow, Kjeld
AU - Bodmer, Nicole
AU - Breese, Erin H.
AU - Hoogendijk, Raoull
AU - Pieters, Rob
AU - Zwaan, Christian Michel
PY - 2021
Y1 - 2021
N2 - No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.
AB - No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.
KW - ALL
KW - infants
KW - inotuzumab ozogamicin
U2 - 10.1111/bjh.17333
DO - 10.1111/bjh.17333
M3 - Journal article
C2 - 33529389
AN - SCOPUS:85100188201
VL - 193
SP - 1172
EP - 1177
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 6
ER -
ID: 256723424